Category: clinical study retractions

New in PNAS: Potti retraction number seven, and a Potti correction

The Proceedings of the National Academy of Sciences (PNAS) has published the seventh retraction for former Duke researcher Anil Potti, who now faces a lawsuit in the midst of an ongoing investigation into his work:

Retraction for “A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities,” by Katherine S. Garman, Chaitanya R. Acharya, Elena Edelman, Marian Grade, Jochen Gaedcke, Shivani Sud, William Barry, Anna Mae Diehl, Dawn Provenzale, Geoffrey S. Ginsburg, B. Michael Ghadimi, Thomas Ried, Joseph R. Nevins, Sayan Mukherjee, David Hsu, and Anil Potti, which appeared in issue 49, December 9, 2008, of Proc Natl Acad Sci USA (105:19432–19437; first published December 2, 2008; 10.1073/pnas.0806674105).

The authors wish to note the following: “We wish to retract this article because we have been unable to reproduce certain key experiments described in the paper regarding validation and use of the colon cancer prognostic signature. This includes the validation performed with dataset E-MEXP-1224, as reported in Fig. 2A, as well as the generation of prognostic scores for colon cancer cell lines, as reported in Fig. 4. Because these results are fundamental to the conclusions of the paper, the authors formally retract the paper. We deeply regret the impact of this action on the work of other investigators.”

The 2008 paper, which has been cited 27 times, according to Thomson Scientific’s Web of Knowledge, was already the subject of a minor 2009 correction: Continue reading New in PNAS: Potti retraction number seven, and a Potti correction

Lack of ethical approval leads to JCO retraction

The Retraction Watch category for “lack of IRB approval” as a reason for retraction — a subject we covered in our most recent Lab Times column — is growing. First there were the 90-odd retractions by Joachim Boldt, then three by Australian researchers studying Aussie-rules football players. Now, we learn that the Journal of Clinical Oncology has retracted a paper over concerns that the authors failed to obtain ethical approval to conduct their study.

The 2010 publication, by researchers at Saitama Medical University in Japan, reported on an analysis of 314 lymphoma patients being treated with chemotherapy — some, and perhaps none, of whom knew they were being studied.

Here’s the notice, which appeared this month: Continue reading Lack of ethical approval leads to JCO retraction

More on Hattori case from co-author: Did grudge lead to scientist’s fall?

We have an update on the case of Yoshiyuki Hattori, the Japanese endocrinologist who has had a half-dozen papers retracted because of issues involving reused data. We’ve reported on some of those retractions, and report on three new ones here.

As a trainee, Hattori spent some time in England, where he met Steven Gross, a prominent pharmacology researcher at Cornell. Gross was impressed with the young physician-scientist, and invited him back to his New York City laboratory to do a postdoc.

Gross’ name appears on one of the retracted articles, “NO suppresses while peroxynitrite sustains NF-κB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO,” which appeared in 2004 in the journal Cardiovascular Research and has been cited 42 times, according to Thomson Scientific’s Web of Knowledge.

According to the notice: Continue reading More on Hattori case from co-author: Did grudge lead to scientist’s fall?

Why did Science partially retract the XMRV-chronic fatigue syndrome paper?

If past experience is any indication, billions of pixels will be spilled in the coming days as scientists and advocates debate the latest twist in the story of XMRV, or xenotropic murine leukemia-related virus, and chronic fatigue syndrome (CFS). Today’s news is that Science is partially retracting a 2009 paper by Judy Mikovits and colleagues, including Vincent Lombardi, purporting to show a link between the virus and the syndrome — a paper about which they issued an Expression of Concern in May. The retraction is of a table and a figure — more on that in a bit.

In an excellent blow-by-blow account in Science of the nearly 20-year-long saga, also out today, Jon Cohen and Martin Enserink review the unusual circumstances of that Expression of Concern. Science editor-in-chief Bruce

Alberts and Science Executive Editor Monica Bradford had first suggested that Mikovits and her co-authors retract the paper voluntarily. “Science feels it would be in the best interest of the scientific community,” they wrote in a 26 May letter. Mikovits was livid and questioned Alberts’s motives. “Who wrote that letter? I don’t think it was Science,” she says. The co-authors thought the retraction request was premature, too. “What if we walk away from this based on contamination and it’s not contamination?” Lombardi asked. “You’ve got to give us time to figure this out.”

Alberts stresses that they floated the retraction idea because Science already planned to publish the Expression of Concern. “It wasn’t a public call for retraction,” he notes, emphasizing that the recipients shared it with the media. He also does not think it would have been premature, although he says it’s often a tough call whether to retract a paper. “Ultimately, it requires expert judgment and a lot of sensitivity to the issues,” he says. “We had lost confidence in the results.”

As Science noted in May, two studies accompanied the May Expression of Concern Continue reading Why did Science partially retract the XMRV-chronic fatigue syndrome paper?

Nature Medicine paper by former Montreal Heart Institute researcher Zhiguo Wang unlikely to be retracted

We’ve been reporting on the case of Zhiguo Wang, the Montreal Heart Institute researcher who was dismissed earlier this month for scientific misconduct. In the announcement about Wang’s dismissal, the institute said it had requested the retraction of three papers other than the two that Wang had himself retracted earlier this summer, making a total of five.

We’ve been following up with journals that published Wang’s work, with the help of eagle-eyed Retraction Watch readers, and last week reported on the first of those three additional retractions, in the Journal of Cell Science. Late last week, we heard from Juan Carlos Lopez, the chief editor of Nature Medicine, which had published a paper by the group. Lopez had earlier said he was waiting for a Montreal Heart Institute report on their findings. He tells us it’s unlikely the Nature Medicine paper will be among those retracted: Continue reading Nature Medicine paper by former Montreal Heart Institute researcher Zhiguo Wang unlikely to be retracted

Group retracts Nature Immunology paper for figure irregularities after posting a correction to Science

courtesy NPG

We’re following the case of a group that recently retracted a Nature Immunology paper for figure irregularities, soon after being forced to correct images in a Science paper for similar reasons.

The Nature Immunology paper, “The helminth product ES-62 protects against septic shock via Toll-like receptor 4–dependent autophagosomal degradation of the adaptor MyD88,” has been cited just twice since it appeared online in February 2011, according to Thomson Scientific’s Web of Knowledge. The retraction notice, which appeared online on July 19: Continue reading Group retracts Nature Immunology paper for figure irregularities after posting a correction to Science

Another retraction of IRB-free paper from Aussie sports medicine group

There’s another retraction from the Australian researchers who failed to obtain institutional review board (IRB) approval for their studies of rugby players and footballers.

The 2010 paper, in BMC Musculoskeletal Disorders — which had already retracted two other articles from the group — was titled “The effect of a sports chiropractic manual therapy intervention on the prevention of back pain, hamstring and lower limb injuries in semi-elite Australian Rules footballers: A randomized controlled trial.”

The editor of the journal had added this comment to the PDFs associated with the paper on August 3, a day after our post on the previous two retractions: Continue reading Another retraction of IRB-free paper from Aussie sports medicine group

Publishing scandal costs nursing researcher his post at online university

Scott Weber

Scott Weber, the nursing researcher accused of manipulating references and other publishing misconduct in at least seven retracted articles, has lost his position at Walden University, Retraction Watch has learned.

We noticed the other day that Weber’s name had disappeared from the Walden website and put in a call to the institution. A source there told us that Weber — a part-time faculty member who had been hoping for a full-time appointment at the school — apologized when confronted about the fraud.

The source, who did not want to be identified, said Continue reading Publishing scandal costs nursing researcher his post at online university

Duke sued over Potti case

Anil Potti, courtesy Duke

From the “not terribly surprising” department: Eight patients — or their estates — who enrolled in clinical trials at Duke overseen by Anil Potti and colleagues have sued the university.

The 90-page lawsuit, which names Duke, Potti, Potti’s boss Joseph Nevins, CancerGuide Diagnostics (in which Potti and Nevins had an interest), among others, does a thorough job of documenting the case. In particular, it reviews the history of the trials, which were stopped in 2009, restarted, and then stopped for good as more and more issues came to light. It emphasizes, as you would expect, that Duke and the Potti team were warned repeatedly about problems in their work, notably by Keith Baggerly and a colleague.

Potti and colleagues have, as Retraction Watch readers will remember, now retracted five papers.

The plaintiff’s attorney, Thomas Henson, told Raleigh-Durham’s ABC11: Continue reading Duke sued over Potti case

Dutch university investigating psych researcher Stapel for data fraud

Tilburg University in the Netherlands has suspended the prominent social psychologist Diederik Stapel over concerns that he fabricated data in his published studies. According to a translation of a press release from the school, Stapel, professor of cognitive social psychology and dean of Tilburg’s School of Social and Behavioral Sciences, “has committed a serious breach of scientific integrity by using fictitious data in his publications.”

The release says the rector of Tilburg has set up a committee to investigate Stapel’s manuscripts and report back by October. Heading the panel is W.J.M. Levelt, former* president of the Royal Dutch Academy of Sciences and professor emeritus at the Radboud University in Nijmegen.

What the release does not specify, however, is which of Stapel’s many publications — a Medline search comes up with at least 45 bearing his name — are implicated. Continue reading Dutch university investigating psych researcher Stapel for data fraud